Washington (AP) – Robert F. Kennedy Jr. has confirmed his intention to garner the political backing necessary to assume the role of the nation’s leading health official, stating, “I pledge to work within” the longstanding federal framework for vaccine approval and administration. However, his regulatory body has hinted at significant alterations that may obscure the landscape of available vaccines.
According to reports from the Food and Drug Administration, they plan to “unleash a massive framework” for vaccine testing and approval, as articulated by Commissioner Marty McCurry. While details remain undisclosed, this initiative is being managed by the agency’s newly appointed vaccine chief, Dr. Vinai Prasad, a noted critic of the FDA’s Covid-19 booster policy.
McCurry, along with other officials from the Trump administration, is taking unprecedented steps that sow doubt regarding Covid-19 vaccinations planned for the upcoming fall, which includes delays affecting FDA scientists. Full approval for the Novavax shot has been stalled, limiting its availability primarily to those at heightened risk from the virus. Additionally, they have suggested seasonal adjustments to align with the circulating virus strains, which necessitates further testing for new products.
These changes extend beyond various health agencies.
The Centers for Disease Control and Prevention are yet to incorporate recent recommendations from a leading advisory panel regarding new meningitis vaccines or expanded RSV vaccination initiatives. During a meeting with Kennedy’s “Make America Healthy Again” allies, it was communicated that they should prepare for the cessation of Covid-19 booster recommendations for children. Concurrently, researchers nationwide have lost funding from the National Institutes of Health aimed at investigating vaccine hesitancy.
“It appears RFK Jr. is working towards making vaccine market entries more challenging,” remarked Dr. Amesh Adalja, a vaccine expert at Johns Hopkins University. “This shift arises from their established history of undermining the value of vaccines.”
Concerns Surrounding Vaccination
During the Senate Health Committee hearing last week, Kennedy inaccurately asserted that the only vaccine rigorously tested against a placebo was for Covid-19.
Sen. Bill Cassidy, a Republican from Louisiana and the committee chair, briefly halted the hearing to clarify, “For the record, that’s untrue.”
In response to worries regarding vaccine testing rhetoric, a cohort of doctors compiled an extensive list of over 120 vaccine clinical trials conducted over the years.
“We aim to address the claim that vaccines have never been tested against a placebo,” stated Dr. Jake Scott, an infectious disease physician from Stanford University leading the initiative.
While some argue that certain substances termed as placebos by material scientists may not meet practical standards, this list evidences that saline solutions are often employed. It’s evident who receives the vaccine versus those in the control group, as vaccines can induce soreness and swelling at the injection sites. Scott noted that alternative options could be employed to mildly stimulate the skin, maintaining the study’s “blinded” nature.
He further emphasized that utilizing a placebo for testing newer versions against an already proven vaccine for the same disease would be ethically questionable.
“We cannot always rely on placebo-controlled trials,” Scott mentioned. “It’s vital to communicate this clearly to the public; however, it becomes challenging amid the extensive misinformation circulating on social media.”
Food and Drug Administration (FDA) Commissioner Marty McCurry addressed the FDA’s press conference on April 22, 2025, regarding the phase-out of oil-based synthetic dyes in national food supplies at the Hubert Humphrey Building Auditorium in Washington.
Trump Officials Confirm Vaccine Strategy
The administration’s commitment to a new vaccine framework comes ahead of Thursday’s meeting where FDA advisors will discuss updates to Covid-19 vaccines planned for the upcoming fall and winter.
The FDA’s credibility has long relied on the independence of its scientific decisions. Although a limited number of political appointees guide the agency, in most instances, approval choices are made by career scientists.
However, standards appear to be evolving. FDA staff were prepared to approve the Novavax vaccine, but this decision faced delays from administrative officials, including McCurry, according to sources familiar with the agency’s challenges who requested to remain anonymous. The vaccine eventually received approval late Friday, albeit with unusual limitations.
Dr. Tracy Beth Hoeg, a political appointee serving as McCurry’s special assistant, was reportedly involved in an unprecedented request for Novavax to conduct new clinical trials for the shot. This requirement emerged shortly after the agency’s longtime vaccine chief, Dr. Peter Marks, was compelled to resign.
Hoeg, along with Makary and Prasad, has been vocal in criticizing the FDA’s management of booster shots during the Covid-19 pandemic, particularly concerning children and young adults. Collectively, they co-authored a 2022 paper arguing that mandating booster shots for younger populations causes more harm than benefit.
However, Novavax isn’t the only vaccine manufacturer impacted by shifts in the FDA’s mindset. Earlier this month, Moderna postponed its timeline for the new combined Covid-and-FLU vaccine until next year after the FDA requested additional efficacy data.
Critics of Covid-19 Boosters Under Scrutiny
In his role overseeing the FDA’s vaccination policies, Prasad is positioned to reverse what he recently termed “numerous failures” in the FDA’s assessment of the risks and benefits associated with the Covid-19 booster.
He raised questions about the yearly benefits of vaccination, suggesting in a recent podcast that he might study about 20,000 seniors this August or September to determine if the latest vaccines effectively prevent community-related hospitalizations.
According to Adalja from Hopkins, “There is a valid debate over who should receive boosters, how frequently they should be administered, and the necessity of boosting low-risk individuals.” However, he stressed that the CDC’s advisory committee on vaccination practices possesses the expertise necessary for making such decisions.
Other experts echo that the updated stock of Covid-19 vaccine targets is not only becoming obsolete, and actual data demonstrates that each annual update yields advantages.
Michael Osterholm, an infectious disease researcher at the University of Minnesota, asserted that it’s “clear and unequivocal” that vaccinations reduce the risk of hospitalization and severe illness among the elderly for four to six months.
Dr. Jesse Goodman of Georgetown University, a former FDA vaccine chief, articulated that this type of research cannot be completed swiftly enough to inoculate millions before the surge in winter cases each year.
“You’re perpetually in clinical trials without having the latest vaccine,” he stated.
___
The Associated Press School of Health Sciences is supported by the Howard Hughes Medical Institution’s Science and Education Media Group and the Robert Wood Johnson Foundation. The AP maintains sole responsibility for all content.
Source: apnews.com